Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...